← SearchDEVELOPING A NOVEL THERAPEUTIC TARGET IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA$347,100FY2022Department of the ArmyDODDana-Farber Cancer Institute, Inc.InvestigatorsView source on USAspending →